key: cord-0328287-p84e4ax7 authors: Dravid, A.; Kashiva, R.; Khan, Z.; Bande, B.; Memon, D.; Kodre, A.; Potdar, P.; Mane, M.; Tamboli, A.; Pawar, V.; Patil, D.; Banerjee, D.; Bhoite, K.; Shinde, A.; Pharande, R.; Kalyani, S.; Raut, P.; Bapte, M.; Saldanha, C.; Chandak, D.; Ajani, F.; Mehta, A.; Reddy, M. S.; Bhayani, K.; S S, L.; P D, V.; Srivastava, S.; Khandelwal, S.; More, S.; Shakeel, A.; Pawar, M.; Nande, P.; Harshe, A.; Kadam, S.; Halikar, S.; Kamal, N.; Andrabi, D.; Bodhale, S.; Raut, A.; Gawande, P.; Bhandari, A.; Wasmatkar, N.; Sarkar, A.; Chandrashekhar, S.; Butiyani, P.; Akhade, G.; Abnave, A.; Raman, C.; Basade, S. title: Epidemiology, clinical presentation and management of COVID-19 associated Mucormycosis: A single center experience from Pune, Western India. date: 2021-09-22 journal: nan DOI: 10.1101/2021.09.15.21263622 sha: 4d1c7a68a89ad551dc13df687ad8fcdb85e27540 doc_id: 328287 cord_uid: p84e4ax7 Background: The second COVID-19 wave in India, triggered by the Delta variant,has been associated with an unprecedented increase in cases of COVID-19 associated Mucormycosis(CAM), mainly Rhino-orbito-cerebral mucormycosis(ROCM).The primary reason appears to be an unusual alignment of multiple risk factors in patients like prevalence of hypoxia, uncontrolled diabetes mellitus, indiscriminate use of steroids, high iron levels and immune dysfunction. Methods: This retrospective cohort study was conducted at Noble hospital and Research Centre (NHRC), Pune, Western India between 1st April 2020 and 1st August 2021 to identify patients admitted with CAM. The primary endpoint was incidence of all cause mortality due to CAM. Secondary outcomes studied were need for mechanical ventilation and intensive care unit(ICU) admission. Baseline and time dependent risk factors significantly associated with death due to CAM were identified by Relative risk estimation. Results: 59 patients were diagnosed with Mucormycosis at NHRC (58 ROCM, 1 Renal (disseminated) mucormycosis). Median age of the cohort was 52(IQR: 41,61) years and it included 20.3% females. Median duration from first positive COVID-19 RT PCR test to diagnosis of Mucormycosis was 17(IQR: 12,22) days. 90% patients were diabetic with 30% being newly diagnosed at the time of COVID-19 admission and 89% having uncontrolled sugar level (HbA1c > 7%). All patients were prescribed steroids during treatment for COVID-19. 56% patients were prescribed steroids for non-hypoxemic, mild COVID (irrational steroid therapy) while in 9%, steroids were indicated but were prescribed in inappropriately high dose. Majority of the patients were treated with a combination of surgical debridement(94%), intravenous Amphotericin B(91%) and concomitant oral Posoconazole therapy(95.4%). 74.6% patients were discharged after clinical and radiologic recovery while 25.4% (15 patients) died. On Relative risk analysis, CT severity score during COVID-19 admission [≥]18 (p=0.017), presence of orbital symptoms(p=0.002), presence of diabetic ketoacidosis(p=0.011) and cerebral involvement by Mucor(p=0.0004) were associated with increased risk of death. Duration of Amphotericin B therapy of [≥] 21 days was associated with statistically significant reduction in mortality(p=0.002). Conclusions: CAM is an uncommon, rapidly progressive, angioinvasive, opportunistic fungal infection which is fatal if left untreated. Combination of surgical debridement and antifungal therapy leads to clinical and radiologic improvement in majority of cases. 1 1 oxycholate (1 mg/kg)) were used for patients. The duration of Amphotericin B treatment was 2 9 3 decided depending on the site of involvement (3 weeks for only paranasal sinus involvement, 4 2 9 4 weeks for orbital, lung and disseminated Mucormycosis and 6 weeks for Central nervous system 2 9 5 (CNS) Mucormycosis). Oral Posaconazole (delayed release tablets, 300 mg twice a day on Day 1 2 9 6 and then 300 mg once a day) was started along with Amphotericin B treatment and continued 2 9 7 after discharge from hospital for a period of 1 to 3 months depending on local control of disease 2 9 8 and discretion of Infectious disease physician. In patients with concomitant chronic kidney 2 9 9 disease, intravenous Posaconazole or Isavuconazole followed by step-down to oral therapy was 2) Number of patients who had a clinical and radiologic recovery and were discharged from The use of database for clinical research was approved by the institutional review board Continuous variables were summarized using median and interquartile range (IQR), 3 1 6 while categorical variables were summarized using frequency and percentages. Continuous variables were compared using a Mann Whitney U test. Categorical variables were compared 3 1 8 using Chi-square test, Proportion test and Fishers' exact test. Baseline and time dependent risk 3 1 9 factors significantly associated with death due to CAM were identified by Relative risk analysis. Baseline risk factors included for analysis were age (< 60 years or ≥ 60 years), gender, severity of CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 nervous system (CNS) symptoms, presence of diabetic keto-acidosis, presence of intracranial were > 60 years of age. Fifty-six (95 %) patients had pre-existing or newly diagnosed co-3 3 6 morbidities. Diabetes mellitus (53/59, 89.8 %) was the most common co-morbidity seen in our Barcitinib-2, Idofinib-1, Infliximab-2, Bevacizumab -2 and Itolizumab -1) was prescribed to 3 5 2 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 22, 2021. mg/kg/day in divided doses for 5 to 10 days [67] . Ten patients (16.9 %) were prescribed 2 3 5 5 different steroids during treatment course for COVID-19. 56 % (33/59) patients were prescribed 3 5 6 steroids in the absence of hypoxia (irrational or unscientific steroid use). In 5 (5/54, 9.3%) 3 5 7 patients, Methylprednisolone dose of more than 2 mg/kg/day was prescribed for treatment of 3 5 8 severe COVID-19 (wrong or excess steroid dose). Eleven patients (18.6%) required ICU 3 5 9 admission while 7 (11.9 %) needed noninvasive or invasive ventilation during hospital admission between hospital discharge for COVID-19 to re-admission for Mucormycosis was 7 (IQR: 2.5, 3 7 0 15.5) days. Twenty patients (33.9 %) were diagnosed to have Mucormycosis (suspected fungal 3 7 1 sinusitis, ROCM) during admission for COVID-19. Twenty-seven (45.7 %) were re-admitted 3 7 2 less than 14 days after hospital discharge for COVID-19 while 12 (20.4 %) were re-admitted 3 7 3 after more than 14 days. Headache (43/58, 74.1 %), hemi-facial pain predominantly maxillary 3 7 4 pain (42/58, 72.4 %) and facial swelling (33/58, 56.9 %) were the three commonest presenting 3 7 5 symptoms of ROCM in our cohort (Table 3) . Median duration of symptoms was 6 (IQR: 3, 8.5) 3 7 6 days. Seven patients (11.9 %) had symptoms for more than 2 weeks prior to diagnosis of ROCM. Fifty-eight patients (99%) had rhinal (paranasal sinus) involvement, 33 (56%) had orbital (eyeball, extra-ocular muscles or orbital cavity) and 26 (44.1%) had cerebral involvement (infarcts, cavernous sinus involvement, dural enhancement, frontal lobe abscess, osteomyelitis CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint while no patient had ANC < 1000 cells/mm 3 at admission. Median CRP at admission was 84.7 dimer > 1000 mcg/mL. Median HbA1C level in our cohort was 9.3 (IQR: 8, 12). Ten patients 3 9 0 (10/53, 18.9%) presented with diabetic ketoacidosis. Diagnosis of Mucormycosis was made by Aggressive surgical debridement of involved site and combination antifungal therapy was 3 9 5 standard of care for all ROCM patients in our cohort. Empirical combination anti-fungal therapy 3 9 6 was started after radiologic evidence of invasive sinusitis, pending confirmatory diagnosis by emulsion or Deoxycholate) were the mainstay of antifungal therapy and prescribed to 91.5% (58/59, 98.3%) or Isavuconazole (5/59, 8.5%)) during admission and after discharge till clinician days. FESS with orbital decompression was performed on 94.9 % patients (56/59). Surgical Complications during antifungal therapy and hospital admission are mentioned in Table 4 1 5 6. Fever with chills (78 %), Thrombophlebitis (59.3 %), Hypokalemia (88.1 %), Anemia (57.6 4 1 6 %) and Nephrotoxicity (50.8 %) were the most common complications observed during hospital 4 1 7 admission. Central nervous system (CNS) complications (stroke/cerebritis/brain abscess) were with decreased risk of death (p = 0.002) on Relative risk analysis (Table 7) . All patients who 4 2 6 were discharged from hospital were followed up for a minimum period of 6 weeks to look for We conducted a single-centre, retrospective cohort study of 59 patients with CAM who after control of disease with combined surgical and medical approach. Mortality rate in our 4 4 2 cohort at 6 weeks follow-up was 25.4 %. Majority of the patients in our study were middle-aged (median age: 52 years), of which 4 4 4 nearly two-thirds were male. It has been hypothesized that the effect of estrogen might be 4 4 5 protective in systemic fungal infection, which could have led to lower incidence in females [68] . Case series on CAM by Sharma et al [46] , described diabetes as a risk factor in 90% cases of [58] also noted that more than 80% cases had either pre-existing or new onset hyperglycaemia as a 4 4 9 risk factor. Our study has demonstrated similar findings in that 90 % of included patients were 19. Of the 56 patients who had HbA1c value available, 50 had uncontrolled DM (HbA1c > 7%). Median HbA1c in our cohort was 9.3% while it was 9.6% in the study by Sen et al [55] . Tight Both the RECOVERY trial [17] and WHO COVID-19 [69] guidelines clearly recommend corticosteroids has been identified as an independent risk factor for CAM by the MucoCovi 4 6 3 network [7] . In their retrospective analysis of 187 Indian CAM patients, they found that 78% 4 6 4 (150/187) had received steroid therapy but only 33% patients had received steroids at appropriate 4 6 5 dosages. In 33 % patients (50/150), steroids were not indicated while among 30% (45/150) 4 6 6 patients steroids were indicated but were prescribed in inappropriately high dose [7] . In comparison, in our study, 56 % patients were prescribed steroids for non-hypoxemic, mild to 4 6 8 moderate COVID illness (irrational steroid therapy) while in 8.5 % patients steroids were indicated but were prescribed in inappropriately high dose. Thus there is an urgent need to stop CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint Mucormycosis (0 % versus 8.6 %), increased use of combination antifungal therapy (91% versus 4 8 0 50%) and higher use of combined surgical and medical approach (91% versus 71%). However, 4 8 1 presence of diabetic ketoacidosis (10.9 % versus 8.6 %) and prevalence of cerebral involvement 4 8 2 due to Mucor (44 % versus 23 %) was higher in our cohort than the MucoCovi study [7] . Both the cerebral involvement due to Mucor, mortality rate was 50% which is 5 times higher than among 4 8 6 patients without cerebral involvement. On the other hand, duration of Amphotericin B therapy of 4 8 7 more than 21 days was associated with statistically significant reduction in mortality (p = 0.002). Our study has several limitations. First, this is not a randomized controlled trial, and 4 9 7 therefore unmeasured confounding cannot be ruled out. Second, as for all retrospective studies, and underestimation of mortality due to CAM. Third, we collected data from a single centre in 5 0 0 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 India unlike other multicenter cohort studies [7, 52, 54, 55, 57] . Fourth, an overwhelmed health care 5 0 1 system, inadequate workforce and lack of exhaustive reporting due to surge of cases during 5 0 2 second COVID wave could be responsible for underestimation of co-morbidities, presenting Ferritin, CRP and D-dimer were not available for all patients in the cohort. Sixth, we did not look and contaminated oxygen delivery systems with increased incidence of CAM in our cohort [10] . Seventh, other unexplored factors, including genetic predisposition were not identified. Despite these limitations, this retrospective cohort study adds to the growing body of guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it. 3) World health organization (WHO) Coronavirus disease (COVID-19) dashboard. Available at: https://covid19.who.int. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Duration of hospitalization (days) 9 (6, 14) 8 (6, 13.5) 10 (7, 15) 0.149 Duration of ICU stay (days) 0 (0, 10) 0 (0, 0) 0 (0, 10) 0.303 Duration of ventilation (days) 0 (0, 10) 0 (0, 0) 0 (0, 10) 0.046 COVID-19 vaccine status 0. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 ( . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 22, 2021. ; https://doi.org/10.1101 /2021 doi: medRxiv preprint 1 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Blood urea level (mg/dL) 32 (22, 54) 28 (20 Absolute Lymphocyte count (ALC, cells/mm3) < 1000 7 7 7 7 7 8 7 7 9 7 8 0 7 8 1 7 8 2 7 8 3 7 8 4 7 8 5 7 8 6 7 8 7 7 8 8 7 8 9 7 9 0 7 9 1 7 9 2 7 9 3 7 9 4 7 9 5 7 9 6 7 9 7 7 9 8 7 9 9 8 0